This finding might be of potential therapeutic indication as it would enable drugs such as Nivolumab or Pembrolizumab (that have been demonstrated to be active in tumours who are MSI-H) to work also in tumours that are EpCAM “impaired” or defective. The gene discussed is EPCAM; the disease is neoplasm.